GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis

NYSE:DNA • US37611X2099

8.86 USD
-0.36 (-3.9%)
At close: Feb 23, 2026
8.89 USD
+0.03 (+0.34%)
Pre-Market: 2/24/2026, 4:51:39 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, DNA scores 3 out of 10 in our fundamental rating. DNA was compared to 58 industry peers in the Life Sciences Tools & Services industry. While DNA has a great health rating, there are worries on its profitability. DNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DNA has reported negative net income.
  • In the past year DNA has reported a negative cash flow from operations.
  • In the past 5 years DNA always reported negative net income.
  • In the past 5 years DNA always reported negative operating cash flow.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -500M -1B -1.5B -2B

1.2 Ratios

  • DNA has a Return On Assets of -28.55%. This is in the lower half of the industry: DNA underperforms 74.14% of its industry peers.
  • With a Return On Equity value of -60.66%, DNA is not doing good in the industry: 75.86% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -28.55%
ROE -60.66%
ROIC N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • DNA has a better Gross Margin (72.71%) than 96.55% of its industry peers.
  • In the last couple of years the Gross Margin of DNA has declined.
  • The Profit Margin and Operating Margin are not available for DNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DNA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, DNA has less shares outstanding
  • DNA has a better debt/assets ratio than last year.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • DNA has an Altman-Z score of -7.06. This is a bad value and indicates that DNA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of DNA (-7.06) is worse than 82.76% of its industry peers.
  • DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.06
ROIC/WACCN/A
WACC10.87%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • DNA has a Current Ratio of 4.39. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of DNA (4.39) is better than 68.97% of its industry peers.
  • A Quick Ratio of 4.39 indicates that DNA has no problem at all paying its short term obligations.
  • The Quick ratio of DNA (4.39) is better than 79.31% of its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 45.06% over the past year.
  • Looking at the last year, DNA shows a very negative growth in Revenue. The Revenue has decreased by -17.13% in the last year.
  • The Revenue has been growing by 33.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.86% on average over the next years. This is quite good.
  • Based on estimates for the next years, DNA will show a quite strong growth in Revenue. The Revenue will grow by 10.14% on average per year.
EPS Next Y36.28%
EPS Next 2Y24.51%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue Next Year-23.62%
Revenue Next 2Y-11.27%
Revenue Next 3Y2%
Revenue Next 5Y10.14%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • DNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DNA's earnings are expected to grow with 15.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.51%
EPS Next 3Y15.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (2/23/2026, 8:04:00 PM)

Premarket: 8.89 +0.03 (+0.34%)

8.86

-0.36 (-3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners63.41%
Inst Owner Change9.45%
Ins Owners3.44%
Ins Owner Change-0.01%
Market Cap510.25M
Revenue(TTM)180.61M
Net Income(TTM)-339.55M
Analysts41.82
Price Target10.2 (15.12%)
Short Float %14.49%
Short Ratio6.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.35%
Min EPS beat(2)-15.78%
Max EPS beat(2)30.48%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-15.78%
Max EPS beat(4)30.48%
EPS beat(8)5
Avg EPS beat(8)9.77%
EPS beat(12)6
Avg EPS beat(12)1.99%
EPS beat(16)6
Avg EPS beat(16)-240.57%
Revenue beat(2)1
Avg Revenue beat(2)8.5%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)18.03%
Revenue beat(4)2
Avg Revenue beat(4)9.57%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)23.63%
Revenue beat(8)4
Avg Revenue beat(8)15.72%
Revenue beat(12)8
Avg Revenue beat(12)14.38%
Revenue beat(16)12
Avg Revenue beat(16)23.68%
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)0.34%
EPS NQ rev (3m)0.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.83
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-6.23
EYN/A
EPS(NY)-4.02
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS3.14
BVpS9.72
TBVpS8.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.55%
ROE -60.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.71%
FCFM N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.04%
Cap/Sales 11.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z -7.06
F-Score4
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.26%
EPS Next Y36.28%
EPS Next 2Y24.51%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue 1Y (TTM)-17.13%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-56.39%
Revenue Next Year-23.62%
Revenue Next 2Y-11.27%
Revenue Next 3Y2%
Revenue Next 5Y10.14%
EBIT growth 1Y19.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.58%
EBIT Next 3Y26.55%
EBIT Next 5Y15.81%
FCF growth 1Y53.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.54%
OCF growth 3YN/A
OCF growth 5YN/A

GINKGO BIOWORKS HOLDINGS INC / DNA FAQ

What is the ChartMill fundamental rating of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DNA.


What is the valuation status for DNA stock?

ChartMill assigns a valuation rating of 0 / 10 to GINKGO BIOWORKS HOLDINGS INC (DNA). This can be considered as Overvalued.


How profitable is GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for GINKGO BIOWORKS HOLDINGS INC?

The Earnings per Share (EPS) of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to grow by 36.28% in the next year.